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Abstract
Susceptibility to infection by bacterium such as Bacillus anthracis has a genetic basis in mice and may
also have a genetic basis in humans. In the limited human cases of inhalation anthrax, studies suggest
that not all individuals exposed to anthrax spores were infected, but rather, individuals with
underlying lung disease, particularly asthma, sarcoidosis and tuberculosis, might be more
susceptible. In this study, we determined if polymorphisms in genes important in innate immunity
are associated with increased susceptibility to infectious and non-infectious lung diseases,
particularly tuberculosis and sarcoidosis, respectively, and therefore might be a risk factor for
inhalation anthrax. Examination of 45 non-synonymous polymorphisms in ten genes: p47phox
(NCF1), p67phox (NCF2), p40phox (NCF4), p22phox (CYBA), gp91phox (CYBB), DUOX1, DUOX2,
TLR2, TLR9 and alpha 1-antitrypsin (AAT) in a cohort of 95 lung disease individuals and 95 control
individuals did not show an association of these polymorphisms with increased susceptibility to lung
disease.
Introduction
Since October 2001, when Bacillus anthracis was released
in the United States as an act of bioterrorism, there has
been a greater interest in determining if there are risk fac-
tors for inhalation anthrax infection. Exposure to Bacillus
anthracis spores does not cause infection in all exposed
individuals [1]. Epidemiologic studies of individuals
infected by inhalation anthrax have suggested that a weak-
ened immune system might increase susceptibility to
infection by Bacillus anthracis [2]. Some of the infected
individuals had a history of chronic pulmonary disease,
including asthma, sarcoidosis, and tuberculosis [2-4].
Studies in mice have demonstrated a genetic basis for
anthrax sensitivity [5,6]. For example, macrophages from
C3H mice are 100,000 times more sensitive to the Bacillus
anthracis toxin than macrophages from A/J mice [6]. The
current study examines whether there are genetic poly-
morphisms in humans associated with increased suscepti-
bility to lung disease. Identification of genes associated
with an increased risk of lung disease might identify indi-
viduals who might also be of increased susceptibility to
inhalation anthrax infection.
The NAD(P)H oxidases (NOX) are a family of enzymes
that are essential in host defense against microbial infec-
tion, as reviewed by Quinn and Gauss [7]. The central
enzyme of the NAD(P)H oxidase is a flavin and heme-
containing protein, the most well known being the
phagocytic gp91phox (CYBB, NOX2) protein. gp91phox,
and a number of related proteins including DUOX1 and
DUOX2, are transmembrane proteins which transport
electrons and generate reactive oxygen species (ROS) at
the expense of NADH or NADPH. The activity of the oxi-
dases are highly regulated by accessory proteins, including
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p22phox (CYBA), p47phox (NOXO1, NCF1), p67phox
(NOXA2, NCF2), and p40phox (NCF4). Chronic Granu-
lomatous Disease (CGD), associated with severe, recur-
rent, and chronic non-specific bacterial and fungal
infections, is most commonly caused by mutations in
p47phox,  gp91phox,  p67phox, and p22phox  that severely
compromise the respiratory burst activity of neutrophils.
Görlach et al were the first to identify the presence of at
least one pseudogene copy of the p47phox (NCF1) gene on
chromosome 7q11.23 [8]. By construction of a detailed
physical map of this region Hockenhull et al determined
that there were one normal wildtype copy and two pseu-
dogene copies of NCF1 per chromosome [9]. Heyworth et
al elegantly demonstrated that in some individuals, one of
the pseudogene copies of NCF1, possibly by recombina-
tion or gene conversion, has reverted to the normal
wildtype GTGT sequence (i.e. pseudowildtype) [10].
Thus, individuals with this low frequency polymorphism
of NCF1, have 2 "wildtype" copies and one pseudogene
copy per chromosome [10]. Therefore, individuals (with
2 chromosomes) can have a NCF1 pseudogene: wt copy
ratio of either 2:1, 1:1 or 1:2. Although two groups have
examined the association of the minor 1:1 and 1:2 alleles
with inflammatory bowel disease, the conclusions were in
conflict primarily due to differences in allele frequencies
of the control population and sample size [11,12]. Other
polymorphisms in p47phox, p67phox and gp91phox, have
not been shown to be associated with human disease
other than CGD. Recently p47phox has been shown by
positional cloning to regulate the severity of arthritis in
rats [13]. The H72Y polymorphisms in p22phox (CYBA),
associated with reduced respiratory burst in isolated
human neutrophils [14], but has yet to be shown to be
clearly associated with a disease phenotype [15-17].
DUOX1 and DUOX2, which are expressed in lung epithe-
lium, regulates H2O2 [18-20] and acid [21] production in
the airway but have not been shown to be associated with
lung disease. Mutations in DUOX2 have been shown to be
associated with mild hypothyroidism [22-24].
TLR2 is the receptor for peptidoglycans, lipoteichoic acid,
lipoarabinomannan, mycolylarabinogalactan, and
zymosan. Anthrax infection is thought to be partially
mediated through the TLR2 pathway since TLR2 deficient
mice are resistant to infection by the Sterne strain of Bacil-
lus anthracis and HEK293 cells expressing TLR2, but not
TLR4, are able to signal in response to exposure to heat-
inactivated Bacillus anthracis [25]. Inactivation and killing
of the tuberculosis mycobacterium is also mediated
through TLR2 since macrophages from Tlr2-deficient mice
or human macrophages blocked by anti-TLR2 antibodies
failed to kill the bacteria [26]. Tlr9 and Tlr2 double knock-
out mice display a more pronounced susceptibility to
infection by tuberculosis than single gene knockout mice
[27]. The TLR2  polymorphism R753Q [28] and the
R677W polymorphism in humans [29-31] have been
shown to be associated with increase risk for tuberculosis
infection. The R753Q polymorphism was not associated
with a generalized increased risk of infection, e.g. individ-
uals with R753Q were less responsive to infection by Bor-
relia burgdorferi, which causes Lyme Disease [32] and
R753Q was not associated with increased susceptibility to
Staphylococcus aureus infection [33].
Alpha-1-anti-trypsin (AAT) deficiency has been associated
with increased susceptibility to lung disease, particularly
emphysema [34,35]. Although more than 70 variants
have been described, only a few are associated with
reduced AAT protein expression and/or reduced activity
[35]. Several studies have suggested that simple heterozy-
gosity for mutant alleles of AAT may predispose individu-
als to chronic obstructive lung disease [35-37]. The Z
allele (E366K), which occurs at an allele frequency of
0.01–0.02 in people of European origin, is the most com-
mon allele associated with an increased risk of environ-
mentally induced emphysema [34,38-40]. Homozygous
individuals of the AAT S allele (E288V) are not at risk for
emphysema but compound heterozygotes of the Z and S
allele or a null allele are of increased risk [39,41]. Carriers
of the AAT S and Z alleles are over-represented in individ-
uals with lung cancer [42]
In this study, we attempted to determine whether normal
nonsynonymous genetic variations identified by the Gen-
bank SNP database or previously described in the litera-
ture to be present in the normal population in the genes
for p47phox (NCF1), p67phox (NCF2), p40phox (NCF4),
gp91phox  (CYBB),  p22phox  (CYBA),  DUOX1,  DUOX2,
TLR2, TLR9 and alpha-1 anti-trypsin (AAT) are associated
with an increased susceptibility to tuberculosis, sarcoido-




Anonymized blood samples from control individuals of
European, non-Hispanic origin (n = 95) were obtained
from Kaiser Permanente [43] or from The Scripps
Research Institute GCRC blood drawing program. From a
group of 31,247 participants in a Kaiser Permanente study
of European, non-Hispanic origin [43], all individuals
that had a documented medical history with hospitaliza-
tion for lung diseases: atypical mycobacterial infection (n
= 1), repeated episodes of pneumonia (n = 5), sarcoidosis
(n = 46), and tuberculosis (n = 43), were selected and will
be referred to as the lung disease group (n = 95). The par-
ticipants in the Kaiser Permanente study were members of
Kaiser Permanente attending a Health Appraisal Clinic
and were not selected for underlying acute or chronic dis-Journal of Negative Results in BioMedicine 2006, 5:5 http://www.jnrbm.com/content/5/1/5
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Table 1: Primer List. List of primers used for DNA amplification and ASOH.
Primer name Sequence Temp °C
p47 Ex2F GCTTCCTCCAGTGGGTAGTGGGATC 60
p47 161R GGAACTCGTAGATCTCGGTGAAGC
Primer name Sequence Temp °C
p40 Ex2F GTGCTGAGAGACGAATGTTGG 60
p40 Ex2R GGGCAAGGTTCAGAGGTCAG
p40 Ex5F GACGGGACATCTAGGCTGG 60
p40 Ex5R GGCTCTGGCCATGTGGAAG
p40 Ex8F TCTGAGGCGTGGCTCTGCTG 60
p40 Ex8R GCTCATCTGGGAGCCACTGG
p40 Ex10F ATGACACGGGCTTGTATCAGG 60
p40 Ex10R GAGCTGAAGGTTTTTGCTGGTG
p40 86T TGCTGACATCGAGGAGA 53
p40 86C TGCTGACACCGAGGAGA 53
p40 353G CCTGCTCAGCCTGCCGG 62
p40 353A CCTGCTCAACCTGCCGG 61
p40 815C ACGACCACCGCCCCTCA 58
p40 815T ACGACCACTGCCCCTCA 56
p40 911C GGACGTAGCGCTCATGG 57
p40 911A GGACGTAGAGCTCATGG 55
Primer name Sequence Temp °C
p67 Ex3F CTGGGCACCACAGGGAGCTA 58
p67 Ex3R CACCAAGCCCGCAACACTGA
p67 Ex6F GGGCTTCTATGTGGTTATCTCAA 60
p67 Ex6R CCACAAGGAGGCTACCCTCTTCT
p67 Ex9F GAGCCCAGGCAGGCTCAGTGTCAT 60
p67 Ex10R GCCATCTCAAGGCGGGCTCAAGA
p67 Ex11F GTGTTTCCCCACATCCAC 60
p67 Ex11R AAGGCAGGGAGAGGAACT
p67 Ex13F CAAGGGTTGGGCTAAAGGAC 60
p67 Ex14R GTGTTCTCACACCACAGAGTCAG
p67 542G TGTGGGCAGGCTGTTTC 55
p67 542A TGTGGGCAAGCTGTTTC 53
p67 836C CTGGGCCACGGTCATGT 57
p67 836T CTGGGCCATGGTCATGT 55
p67 983G CCCTGGAAGACCCCAGC 47
p67 983A CCCTGGAAAACCCCAGC 47
p67 1105G CTCAGCCCGGGCTCCCC 50
p67 1105A CTCAGCCCAGGCTCCCC 50
p67 1167C GCTGGAACACACTAAGCTG 54
p67 1167A GCTGGAACAAACTAAGCTG 54
p67 1183C CCAGCTATCGGCCTCGG 57
p67 1183T CCAGCTATTGGCCTCGG 57
Primer name Sequence Temp °C
p22 Ex 2F GACCCTGTCACTGTGCTGTG 61
p22 Ex 2R GAGGCAAACAGCTCACTGTG
p22 Ex 3F CTGAGCTGGGCTGTTCCTT 63
p22 Ex 3R CCACCCAACCCTGTGAGC
p22 Ex 4F CAGCAAAGGAGTCCCGAGT 60
p22 Ex 4R GGAAAAACACTGAGGTAAGT
p22 Ex 5F AAGGCTGAGAACACCCAGG 60
p22 Ex 5R GCTCAGCCTACAGAGCCG
p22 Ex 6F GACCCAGGTCCTGGCTGTG 60+DMSO
p22 Ex 6R AGGCTCACGCGCTCCCGG
p22 85A TCGTGGCCACAGCTGGG 59
p22 85G TCGTGGCCGCAGCTGGG 59Journal of Negative Results in BioMedicine 2006, 5:5 http://www.jnrbm.com/content/5/1/5
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p22 113T GTGGTACTTTGGTGCCT 52
p22 113C GTGGTACTCTGGTGCCT 52
p22 179A GAAGAGGAAGAAGGGCT 51
p22 179C GAAGAGGACGAAGGGCT 53
p22 214C GACAGAAGCACATGACC 53
p22 214T GACAGAAGTACATGACC 51
p22 403G CGCCCATCGAGCCCAAG 59
p22 403A CGCCCATCAAGCCCAAG 56
p22 521C GCTGCGGCGGCGGCG 62
p22 521T GCTGCGGTGGCGGCG 60
Primer name Sequence Temp °C
gp91phox Ex 9F CTAAAGCAGAGATCTAAGTGG 61
gp91phox Ex 9R ACGGTGACCACAGAAATAGCTACCT
gp91phox Ex 11F GTTTCTAGGCATTCTGAGCATCAAG 61
gp91phox Ex 11R GTTCGTAAGCCCTGTACACTATG
gp91phox Ex 12F GTGCCTTGGTTAGAATAGCTTGTG 61
gp91phox Ex 12R GTTGAAGATATCTGGAATCTTCTGTTG
gp91phox 907C TGGTCACTCACCCTTTC 50
gp91phox 907A TGGTCACTAACCCTTTC 48
gp91phox 1414G ACAATGCCGGCTTCCTC 55
gp91phox 1414A ACAATGCCAGCTTCCTC 53
gp91phox 1499A GGAGAAAGATGTGATC 48
gp91phox 1499G GGAGAAAGGTGTGATC 50
Primer name Sequence Temp °C
DUOX1 27F AGAGAGATCTCCTCTCAAGG 58
DUOX1 27R GGTCACCGGAAGAGCTGAG
DUOX1 28F GGGACCTTGGAAGCTCCAG 58
DUOX1 28R GGACGTCGAGAAGTGAAGAG
DUOX1 3532T GGTCTGAGTTCCCCCAG 58
DUOX1 3532C GGTCTGAGCTCCCCCAG 60
DUOX1 3647G GCCGCCGCCGCAGTTTCC 66
DUOX1 3647A GCCGCCGCCACAGTTTCC 63
Primer name Sequence Temp °C
DUOX2 Ex5F ATGTTCTTTCCGACGTGGTGAG 63
DUOX2 Ex6R GCGCCGCCCACATGAGCAG
DUOX2 Ex17F GCCTGCTCAGACTCACAGAG 62
DUOX2 Ex17R ACTCCTTAGGGATCTTGAGCAG
Table 1: Primer List. List of primers used for DNA amplification and ASOH. (Continued)Journal of Negative Results in BioMedicine 2006, 5:5 http://www.jnrbm.com/content/5/1/5
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DUOX2 Ex24F GATGCCTGCCAGATCCCCAG 62
DUOX2 Ex25R TGGCCGCCGTGCCTCGTG
DUOX2 413T TGGAGACCTCGTGTTCG 54
DUOX2 413C TGGAGACCCCGTGTTCG 56
DUOX2 429A CCGAACAGCGCGGGGAC 60
DUOX2 429C CCGACCAGCGCGGGGAC 63
DUOX2 597-8GG GCTTCTCGGGGGGACAG 58
DUOX2 597-8GA GCTTCTCGAGGGGACAG 56
DUOX2 597-8CG GCTTCTCCGGGGGACAG 58
DUOX2 597-8CA GCTTCTCCAGGGGACAG 56
DUOX2 2048G TGTGCTCCGTGTGGTCC 56
DUOX2 2048A TGTGCTCCATGTGGTCC 54
DUOX2 3026G CACTCCCCGGCTGTACA 56
DUOX2 3026A CACTCCCCAGCTGTACA 52
DUOX2 3200T CTTTGCCTTGCCACCCT 53
DUOX2 3200C CTTTGCCTCGCCACCCT 55
Primer name Sequence Temp °C
TLR2 450F ATTGCAAATCCTGAGAGTGG 58
TLR2 688R GCAGTTCCAAACATTCCACG
TLR2 1141F GCCTGTGAGGATGCCTGG 60
TLR2 1827R GCACAGGACCCCCGTGAG
TLR2 1782F GTGCTGTGCTCTGTTCCTG 60
TLR2 2392R TCCCAACTAGACAAAGACTGG
TLR2 170T GAAAAGATTTTGCTGGAC 53
TLR2 170Tdel GAAAAGATTTGCTGGAC 53
TLR2 1892C GGAAGCCCAGGAAAGCT 55
TLR2 1892A GGAAGCACAGGAAAGCT 53
TLR2 2258G CAAGCTGCGGAAGATAA 50
TLR2 2258A CAAGCTGCAGAAGATAA 48
Primer name Sequence Temp °C
TLR9 Ex2F GTGGGTGGAGGTAGAGCTG 60
TLR9 365R ACAGCCAAGAAGGTGCTGG
TLR9 2501F TGCTGCATCACCTCTGTGG 54
TLR9 2794R TGCGGCTGCCATAGACCG
TLR9 13C GTTTCTGCCGCAGCGCC 60
TLR9 13T GTTTCTGCTGCAGCGCC 58
TLR9 237T CACCTCCATGATTCTGA 52
TLR9 237G CACCTCCAGGATTCTGA 54
Table 1: Primer List. List of primers used for DNA amplification and ASOH. (Continued)Journal of Negative Results in BioMedicine 2006, 5:5 http://www.jnrbm.com/content/5/1/5
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TLR9 296C GAACTGCCCGCCGGTTG 58
TLR9 296T GAACTGCCTGCCGGTTG 60
TLR9 2588G AAGTGGGCGAGATGAGG 57
TLR9 2588A AAGTGGGCAAGATGAGG 55
TLR9 2644G CGCAGAGCGCAGTGGCA 60
TLR9 2644A CGCAGAGCACAGTGGCA 58
Primer name Sequence Temp °C
AAT Ex2F TGTCGGCAAGTACTTGGCACAG 60
AAT Ex2R CATAATGCATTGCCAAGGAGAG
AAT Ex3F CAGATGATGAAGCTGAGCCTCG 65
AAT Ex3R AGCCCTCTGGCCAGTCCTGATG
AAT Ex5F GAGCAAGGCCTATGTGACAGG 60
AAT Ex5R AGCTCAACCCTTCTTTAATGTCAT
AAT 374G ACTCCTCCGTACCCTCA 56
AAT 374A ACTCCTCCATACCCTCA 54
AAT 863A GCACCTGGAAAATGAAC 50
AAT 863T GCACCTGGTAAATGAAC 50
AAT 1096G CCATCGACGAGAAAGGG 56
AAT 1096A CCATCGACAAGAAAGGG 54
Table 1: Primer List. List of primers used for DNA amplification and ASOH. (Continued)Journal of Negative Results in BioMedicine 2006, 5:5 http://www.jnrbm.com/content/5/1/5
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ease. All human samples were obtained with written con-
sent. Approvals for the protocols involving the use of
human individuals were obtained from the institutional
review boards of The Scripps Research Institute and Kaiser
Permanente.
p47phox/NCF1 pseudogene: wildtype ratio
Amplification of the region of p47phox exon 2 with the
wildtype GTGT sequence and the pseudogene delGT
sequence were amplified using primers p47phox/NCF1
Ex2F GCTTCCTCCAGTGGGTAGTGGGATC and
p47phox/NCF 161R GGAACTCGTAGATCTCGGTGAAGC
and 32P-labeled p47phox/NCF1 Ex2F primer under stand-
ard PCR conditions for 25 cycles. The 32P-labeled ampli-
fied DNA products were separated on a 10% acrylamide/
urea/TBE sequencing gel. Autoradiography was used to
visualize the wildtype and pseudogene amplified prod-
ucts, which differ by 2 nucleotides in length.
Genotyping of single nucleotide polymorphisms (SNPs) by 
allele specific oligomer hybridization (ASOH)
For the genes of this study, non-synonymous SNPs identi-
fied in Genbank's SNP database and/or non-synonynous
SNPs associated with lung disease were investigated.
Amplification of DNA regions encompassing the SNPs
were amplified using the primers listed in Table 1. ASOH
was performed using standard hybridization conditions
[44] using 32P radiolabeled probes and washing tempera-
tures described in Table 1. Genotyping was determined
following visualization of the hybridized probe by autora-
diography.
Statistics
The Fisher's Exact test was performed with GraphPad
InStat using the raw data entered into a 2 × 2 contingency
table. Power calculations were performed to give the prob-
ability of finding the differences between the gene fre-
quencies as statistically significant, given the sample size.
Results
We examined 95 individuals of European, non-Hispanic
origin with documented medical history with hospitaliza-
tion for lung disease (46 with sarcoidosis, 43 with tuber-
culosis, five with recurrent pneumonia, and one with
atypical mycobacterial infection) and 95 control individ-
uals of European, non-Hispanic origin for differences in
allele frequencies in genes involved in innate immunity.
P47phox/(NCF1)
Examination of the pseudogene: wt copy ratio of control
versus lung disease individuals demonstrated no statisti-
cally significant difference in the frequencies of the pseu-
dogene: wt ratios in the lung disease group as compared
to the control group (Table 2).
p67phox (NCF2), p40phox (NCF4), p22phox (CYBA), 
gp91phox (CYBB), DUOX1, DUOX2
SNPs in the p67phox (NCF2), p40phox (NCF4), p22phox
(CYBA) and gp91phox (CYBB), DUOX1 and DUOX2 genes
were examined. Some SNPs did not occur at a high
enough frequency to be detected in our samples. None of
the allele frequencies differed significantly between the
lung disease and the control groups (Table 3).
TLR2, TLR9, AAT
TLR2, TLR9, and AAT genes were examined. Again, many
SNPs did not occur at high enough frequency to be
observed. Most of the allele frequencies did not differ
between the lung disease and control groups. The TLR2
polymorphism R753Q, associated with tuberculosis, was
not shown to be different between the control or lung dis-
ease group. The TLR2 R677W polymorphism, also associ-
ated with tuberculosis, was not observed in either group.
The R863Q SNP in TLR9 was absent from the lung disease
group indicating that this polymorphism was not associ-
ated with increased lung disease. The AAT S (Glu288Val)
and Z (E366K) alleles, associated with chronic obstructive
lung disease, were examined and there was no difference
in allele frequencies between the control and lung disease
groups (Table 3).
Discussion
Since only a subset of individuals exposed to Bacillus
anthracis spores develop pulmonary disease, the most life-
threatening form of anthrax infection, it would be impor-
tant to identify factors that lead to susceptibility to this
type of infection. This might make it possible to identify
those individuals who are at greatest risk and to provide
them with the most aggressive treatment at the outset of
infection. The ability to thus triage individuals in the case
of a bioterrorism attack would be valuable. Moreover,
understanding genetic susceptibility could lead to better
management of individuals with pulmonary anthrax
infection.
The genetic influences on resistance to infection are very
strong. Indeed, genetic influences on resistance to infec-
Table 2: Pseudogene versus gene ratio. p47phox/NCF1 
pseudogene: wt gene ratio in lung disease and control individuals. 
The data are presented as number of individuals with the 
indicated pseudogene:wt ratio and the number within 
parentheses indicates the calculated frequency.
p47phox/NCF1 
(Pseudogene: wt)
control (n = 59) Lung Disease (n = 64)
2:1 46 (0.78) 51 (0.80)
1:1 13 (0.22) 12 (0.19)
1:2 0 (0) 1 (0.02)Journal of Negative Results in BioMedicine 2006, 5:5 http://www.jnrbm.com/content/5/1/5
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Table 3: Summary of SNP Analyses. SNP analyses of candidate genes in lung disease versus control groups. Numbering of SNPs start 
from the ATG initiator methionine of the cDNA. Data are presented as number of alleles identified divided by total number of alleles 










Exon 6 rs2274064 542 A/G K181R 79/186 (0.43) 91/190 (0.48) 0.98 0.96
Exon 9 rs13306581 836 C/T T279M 0 0
Exon 11 983 G/A R 328K 0 0
Exon 13 1105 G/A G369R 0 0
Exon 13 rs17849502 1167 C/A H389Q 12/190 (0.06) 10/188 (0.05) 0.22
Exon 14 rs13306575 1183 C/T R395W 0 0
p22phox 
(CYBA)






Exon 2 85 A/G T29A 0 0
Exon 2 113 T/C F38S 0 0
Exon 3 179 A/C K60S 4/190 (0.02) 0 0.06
Exon 4 rs4673 214 C/T H72Y 61/180 (0.34) 60/190 (0.37) 0.99 0.61
Exon 6 403 G/A E135K 0 0
Exon 6 rs17845095 521 C/T A174V 93/176 (0.41) 88/190 (0.46) 0.99 0.79
p40phox 
(NCF4)






Exon 2 rs13057803 86 T/C I29T 0 0
Exon 5 rs9610595 353 G/A S118N 0 0
Exon 8 815 G/A P272L 30/190 (0.16) 29/190 (0.15) 0.68 0.22
Exon 10 rs5995361 911 C/A A304E 0 0
gp91phox 
(CYBB)






Exon 9 rs28935182 907 C/A H303N 0 0
Exon 11 rs13306300 1414 G/A G472S 0 0
Exon 12 rs28935181 1499 A/G D500G 0 0






Exon 27 rs2458236 3532 T/C F1178L 64/184 (0.35) 56/154 (0.36) 0.99 0.63
Exon 28 rs2292466 3647 G/A R1216H 0 0






Exon 5 rs2001616 413 C/T P138L 26/188 (0.14) 22/190 (0.12) 0.59
Exon 5 rs7166994 429 C/A D143E 0 0
Exon 6 rs2467827 598 G/A G200R 1/188 (0.01) 1/190 (0.01) 0.05
Exon 17 rs8028305 2048 G/A R683H 0 0
Exon 24 rs2277611 3026 G/A A1009Q 0 0
Exon 25 rs269868 3200 T/C L1067S 22/186 (0.12) 15/190 (0.08) 0.5






Exon 2 rs3840097 510Tdel F170Lfs 0 0
Exon 2 rs5743699 1232C/T T411I nd 0
Exon 2 rs5743702 1667T/C I556T nd 0
Exon 2 rs5743703 1736G/A R579H nd 0Journal of Negative Results in BioMedicine 2006, 5:5 http://www.jnrbm.com/content/5/1/5
Page 9 of 11
(page number not for citation purposes)
tion appear to be greater than genetic influences on cancer
or cardiovascular disease [45]. In the past few decades a
considerable number of polymorphisms have been
shown to cause infectious disease susceptibility in mice
[6] and in humans [28,31,46]. Because infections caused
by Bacillus anthracis are rare it was impossible to examine
candidate polymorphisms in patients who actually devel-
oped pulmonary anthrax. Instead, it was necessary to use
surrogate infections such as unusual mycobacterial infec-
tions, recurrent pneumonia, and tuberculosis or examine
lung diseases such as sarcoidosis, which has been reported
in cases of inhalation anthrax, for this study. The "lung
disease group" in this study represented all the individuals
with documented hospitalization for lung disease from a
collection of 31,247 individuals of European, non-His-
panic origin unselected for any particular acute or chronic
health problem. Candidate genes were chosen on the
basis of their role in immunity against chronic infection as
well as their participation in the innate immune response.
This is a reasonable approach, since defects in the
immune system generally increases susceptibility not to a
single organism, but rather to multiple organisms that
share some features in the pathogenesis of the disease that
they produce.
Our analyses of genes of the NAD(P)H oxidase, p47
(NCF1),  p67phox  (NCF2),  p40phox  (NCF4),  p22phox
(CYBA), and gp91phox  (CYBB), as well as other genes
involved in innate immunity such as DUOX1 and 2, TLR2,
TLR9 and AAT demonstrated that there were no differ-
ences between the control and lung disease group com-
prised of primarily sarcoidosis and tuberculosis
individuals. There may, of course, be many other poly-
morphisms that affect susceptibility to Bacillus anthracis.
Although the genes that we chose seemed to be reasona-
ble candidates; there are many additional genes encoding
products that could be important in effecting the course of
anthrax in humans. For example, it has been suggested
that susceptibility to Bacillus anthracis might involve
myD88 [25]. Furthermore, susceptibility to infection by
tuberculosis may be altered by variations in the vitamin D
receptor gene [47]. Similarly, sarcoidosis has been shown
to be associated with particular alleles in BTNL2 [48,49],
IL18 [50], and IFNa [51], and SLC11A1 [52].
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Exon 2 rs5743704 1892C/A P631H 9/184 (0.05) 8/188 (0.04) 0.18
Exon 2 2029C/T R677W nd 0
Exon 2 rs5743706 2143T/A Y715N nd 0
Exon 2 rs5743707 2145T/G Y715Stop nd 0
Exon 2 rs5743708 2258G/A R753Q 2/182 (0.01) 4/188 (0.02) 0.05
Exon 2 2304G/T E768D nd 0






Exon 2 rs5743842 13 C/T R5C 2/190 (0.01) 0 0.05
Exon 2 rs5743843 237T/G H79Q 0 0
Exon 2 rs5743844 296 C/T P99L 0 0
Exon 2 rs5743845 2588 G/A R863Q 6/170 (0.04) 0/186 (0*) 0.14
Exon 2 rs5743746 2644 G/A A882T 0 0
AAT 
(SERPINA1)






Exon 2 rs709932 374G/A R125H 38/178 (0.21) 29/182 (0.16) 0.85 0.31
Exon 3 rs17580 863A/T E288V 5/190 (0.03) 4/190 (0.02) 0.1
Exon 4 rs28929474 1096G/A E366K 4/192 (0.02) 2/190 (0.01) 0.07
Table 3: Summary of SNP Analyses. SNP analyses of candidate genes in lung disease versus control groups. Numbering of SNPs start 
from the ATG initiator methionine of the cDNA. Data are presented as number of alleles identified divided by total number of alleles 
examined. Numbers within parentheses are the calculated allele frequencies. Power calculations were performed using number of 
subjects. (Continued)Journal of Negative Results in BioMedicine 2006, 5:5 http://www.jnrbm.com/content/5/1/5
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